Integrating UN Convention on the Rights of Persons with Disabilities in Drug Labeling Integrating UN Convention on the Rights of Persons with Disabilities in Drug Labeling The need for inclusivity in drug labeling is paramount for ensuring compliance with the UN Convention on the Rights of Persons with Disabilities (CRPD). This step-by-step guide provides a comprehensive framework for regulatory compliance consulting in the context of drug labeling, particularly in the United States. By placing an emphasis on practical actions, documentation expectations, and tangible outcomes, this guide aims to help pharmaceutical and medical device companies navigate the complexities of integrating these…

WHO vs UNESCO Health Ethics Guidelines: Key Differences WHO vs UNESCO Health Ethics Guidelines: Key Differences In today’s global landscape of healthcare and research, understanding the regulatory frameworks established by organizations such as the World Health Organization (WHO) and the United Nations Educational, Scientific and Cultural Organization (UNESCO) is essential for compliance and ethical governance. This article provides a step-by-step guide to discerning the key differences between WHO and UNESCO health ethics guidelines, laying out actionable frameworks for regulatory compliance consulting in the United States. Step 1: Understanding the Role and Authority of WHO and UNESCO The first step in…

Role of UNDP in Strengthening National Regulatory Capacity Role of UNDP in Strengthening National Regulatory Capacity The United Nations Development Programme (UNDP) plays a pivotal role in enhancing national regulatory capacity in various countries, especially in the context of healthcare and pharmaceuticals. This comprehensive guide outlines the steps involved in understanding and implementing UNDP initiatives aimed at regulatory compliance and capacity strengthening. By focusing on the integration of global health policy, bioethics, and regulatory harmonization, this tutorial provides actionable insights into enhancing national regulatory frameworks. Step 1: Understanding UNDP’s Mandate and Framework The first step in strengthening national regulatory capacity…

UN Sustainable Development Goals (SDGs) and Their Link to Regulatory Policy UN Sustainable Development Goals (SDGs) and Their Link to Regulatory Policy The United Nations Sustainable Development Goals (SDGs) represent a global framework aimed at addressing pressing societal challenges while promoting sustainable development by 2030. Regulatory compliance consulting professionals must understand how these goals interlink with regulatory policies to ensure oversight of health-related issues, bioethics, and global health policy. This article provides a comprehensive, step-by-step guide tailored for regulatory affairs professionals focusing on the implementation of SDGs within the context of regulatory frameworks, particularly in the U.S. Step 1: Understanding…

Understanding UNESCO’s Bioethics Declarations in Clinical Research Understanding UNESCO’s Bioethics Declarations in Clinical Research The UNESCO declarations regarding bioethics play a crucial role in the framework of clinical research, particularly as they pertain to the ethical principles guiding studies involving human subjects. The implementation of these principles within the scope of GCP compliance services is essential for ensuring both ethical integrity and regulatory compliance. This step-by-step guide will equip regulatory affairs professionals with the necessary tools to understand and implement UNESCO’s bioethics declarations in their clinical research practice. Step 1: Familiarizing with UNESCO’s Bioethics Declarations The first step in implementing…

EMA-CAT Quality Dossier Hotspots: CMC Issues That Delay ATMP Approvals in 2023 EMA-CAT Quality Dossier Hotspots: CMC Issues That Delay ATMP Approvals in 2023 The development and approval of Advanced Therapy Medicinal Products (ATMPs) require meticulous compliance with regulatory expectations, particularly in the context of manufacturing and quality. Understanding the intricacies of the European Medicines Agency’s (EMA) Committee for Advanced Therapies (CAT) expectations is critical for achieving timely approvals. This article presents a step-by-step tutorial on navigating common Chemistry, Manufacturing and Controls (CMC) issues that frequently cause delays in authorization processes through the Marketing Authorization Application (MAA) for ATMPs, focusing…

EU MAA via CMDh Coordination: Document Set Checklist for US Regulatory Teams EU MAA via CMDh Coordination: Document Set Checklist for US Regulatory Teams The submission and approval of a Marketing Authorisation Application (MAA) within the European Union (EU) can be a complex process. For US regulatory teams, understanding the Coordination Group for Mutual Recognition and Decentralised Procedures – human (CMDh) is essential for ensuring compliance in cross-border pharmaceutical regulations. This guide presents a step-by-step tutorial to navigate the intricacies of the EU MAA via CMDh coordination, providing a comprehensive document set checklist tailored for US pharmaceutical professionals. Step 1:…

EMA-CAT ATMP Classification: What US Sponsors Should Prepare Before EU Advice EMA-CAT ATMP Classification: What US Sponsors Should Prepare Before EU Advice The process of navigating the intricate landscape of Advanced Therapy Medicinal Products (ATMPs) in the European Union (EU) requires meticulous planning and an understanding of both regulatory strategies and documentation requirements. This article aims to provide a comprehensive, step-by-step guide for US sponsors on the preparations needed before seeking advice from the European Medicines Agency’s Committee for Advanced Therapies (EMA-CAT) regarding ATMP classification. Step 1: Understand the ATMP Classification Framework Before initiating your application for EU advice, it’s…

CMDh Referral Outcomes: Risk Mitigation Tips for US-Based MA Holders in 2023 CMDh Referral Outcomes: Risk Mitigation Tips for US-Based MA Holders in 2023 In the ever-evolving landscape of pharmaceutical regulation, understanding the implications of CMDh referrals and the related EMA-CAT processes is crucial for maintaining regulatory compliance and ensuring the ongoing success of marketing authorizations (MAs) in the European Union. While this article is particularly relevant for US-based MA holders, the methodologies described herein are applicable to other stakeholders involved in global drug development and distribution. This comprehensive guide will walk you through the critical steps of navigating CMDh…

EMA Variations vs FDA Supplements: Change Strategy for US–EU Lifecycle Management EMA Variations vs FDA Supplements: Change Strategy for US–EU Lifecycle Management Step 1: Understand the Regulatory Framework for Variations and Supplements Before engaging in the management of drug lifecycle changes, it is essential to establish a firm understanding of the regulatory frameworks governing EMA variations and FDA supplements. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) provide distinct pathways for modifying existing marketing authorizations. Compliance with these frameworks is crucial for maintaining compliance and ensuring patient safety. The EMA classifies variations into three categories:…